Overview

Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The main objective of this study will be to obtain data on the efficacy of elsiglutide in preventing Chemotherapy Induced Diarrhea (CID) in patients with colorectal cancer receiving 5-FU based chemotherapy (FOLFOX4 or FOLFIRI regimen) in comparison to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Helsinn Healthcare SA